Is Bcr-Abl expression relevant for the survival of cancer stem cells in chronic myeloid leukaemia (CML)?

被引：0
|
作者：
Helgason, G. V. [1 ]
Hamilton, A. [1 ]
Myssina, S. [2 ]
Jorgensen, H. G. [1 ]
Bhatia, R. [3 ]
Modi, H. [3 ]
Schemionek, M. [4 ]
Koschmieder, S. [4 ]
Brunton, V.
Holyoake, T. L. [1 ,5 ]
机构：
[1] Univ Glasgow, Fac Med, Paul Ogorman Leukaemia Res Ctr, Sect Expt Haematol,Div Canc Sci & Mol Pathol, Glasgow, Lanark, Scotland
[2] Newcastle Univ, Sch Med, Newcastle Upon Tyne, Tyne & Wear, England
[3] City Hope Hosp, Dept Haematol, Duarte, CA USA
[4] Univ Munster, Dept Haematol & Med Oncol, D-4400 Munster, Germany
[5] Univ Edinburgh, Inst Genet & Mol Med, Div Canc Biol, Edinburgh, Midlothian, Scotland
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2010年 / 149卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
178
引用
收藏
页码：72 / 72
页数：1
相关论文
共 50 条
  • [11] BCR-ABL peptide boost vaccinations can maintain anti-BCR-ABL immune responses in chronic myeloid leukaemia (CML) patients
    Rojas, J. M.
    Knight, K.
    Watmough, S.
    Bell, J.
    Wang, L. H.
    Clark, R. E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 63 - 63
  • [12] BCR-ABL insufficiency for the transformation of human stem cells into CML
    Matioli, GT
    MEDICAL HYPOTHESES, 2002, 59 (05) : 588 - 589
  • [13] Detection of BCR-ABL transcripts in chronic myeloid leukaemia by nested PCR
    Otazú, IB
    Zalcberg, I
    Tabak, DG
    Seuánez, HN
    LEUKEMIA RESEARCH, 1999, 23 (02) : 185 - 190
  • [14] Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
    Clapper, Erin
    Wang, Sicong
    Raninga, Prahlad V.
    Di Trapani, Giovanna
    Tonissen, Kathryn F.
    ANTIOXIDANTS, 2020, 9 (03)
  • [15] CCN3 expression is reduced as a result of Bcr-Abl kinase in chronic myeloid leukaemia
    不详
    JOURNAL OF CLINICAL PATHOLOGY, 2005, 58 (05) : 473 - 473
  • [16] Increase of BCR-ABL/ABL Ratio That Corresponds to BCR-ABL Mutation Detection In Chronic Myeloid Leukemia (CML) Patients Treated by Imatinib (IM)
    Tsaur, Grigory
    Popov, Alexander
    Ivanova, Anna
    Yakovleva, Yulia
    Riger, Tatyana
    Plekhanova, Olga
    Ivanets, Yulia
    Shorikov, Egor
    Saveliev, Leonid
    Fechina, Larisa
    FASEB JOURNAL, 2011, 25
  • [17] EVALUATION OF BCR-ABL MONITORING IN CHRONIC MYELOID LEUKEMIA (CML) IN CLINICAL PRACTICE
    Romvari, Edie
    Bollu, Vamsi
    Morlock, Robert
    Teitelbaum, April
    Henk, Henry
    Garcia, Reynaldo
    ONCOLOGY NURSING FORUM, 2011, 38 (02) : E160 - E161
  • [18] Direct evidence that chronic myeloid leukaemia (CML) cells can express BCR-ABL junctional oligopeptides in association with class IHLA.
    Clark, RE
    Hill, SC
    Lill, JR
    Norbury, LC
    Christmas, SE
    Bonner, PLR
    Creaser, CS
    Rees, RC
    BLOOD, 2000, 96 (11) : 510A - 511A
  • [19] Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia
    Kabarowski, JHS
    Witte, ON
    STEM CELLS, 2000, 18 (06) : 399 - 408
  • [20] Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?
    Doggrell, Sheila A.
    Christensen, Anne-Marie
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (01) : 154 - 163
12345